Momelotinib May Become ‘No. 1 Choice’ for Second-Line Therapy in Myelofibrosis, Expert Says

Video

Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center.

After demonstrating benefit in reducing anemia and splenic symptoms, momelotinib could become the optimal treatment option in the second-line setting for patients with myelofibrosis, according to Srdan Verstovsek, MD, PhD.

During the 2022 American Society of Hematology (ASH) Annual Meeting, CancerNetwork® spoke with Verstovsek, the United Energy Resources, Inc., Professor of Medicine and a hematologist-oncologist at the University of Texas MD Anderson Cancer Center in Houston, about findings from a pooled analysis of 3 phase 3 trials assessing momelotinib in patients with myelofibrosis.

In addition to feeling positive about the agent’s potential FDA approval in June 2023, Verstovsek stated that momelotinib could be the best treatment option for patient in the second-line setting.

Transcript:

When June of 2023 comes where we expect the decision by FDA as to whether [momelotinib should be] approved or not, I hope it will be because the study was really well done. It clearly shows the benefit in anemia and splenic symptoms. [We must quickly] find its place in the management of our patients with myelofibrosis, particularly in the setting the phase 3 randomized study was done in: the second-line setting where we struggle.

We don't have any therapy for anemia. If a patient has low platelets, this drug can be given to [them]. Of course, it can control the spleen if it has major problems. I would say that this drug may become the No. 1 choice of therapy in the second-line setting in myelofibrosis in the very near future.

Reference

Verstovsek S. Momelotinib (MMB) long-term safety: pooled data from three phase 3 randomized-controlled trials (RCTs). Presented at 2022 American Society of Hematology (ASH) Meeting and Exposition; December 10-13, 2022; abstract 4348.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content